Form 8-K - Current report:
SEC Accession No. 0000950170-22-016850
Filing Date
2022-08-11
Accepted
2022-08-11 16:06:07
Documents
14
Period of Report
2022-08-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K eldn-20220811.htm   iXBRL 8-K 53474
2 EX-99.1 eldn-ex99_1.htm EX-99.1 250240
3 GRAPHIC img20068692_0.jpg GRAPHIC 7613
  Complete submission text file 0000950170-22-016850.txt   443478

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT eldn-20220811.xsd EX-101.SCH 2463
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT eldn-20220811_pre.xml EX-101.PRE 9839
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT eldn-20220811_lab.xml EX-101.LAB 13352
8 EXTRACTED XBRL INSTANCE DOCUMENT eldn-20220811_htm.xml XML 4703
Mailing Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612
Business Address 19900 MACARTHUR BLVD. SUITE 550 IRVINE CA 92612 949-238-8090
Eledon Pharmaceuticals, Inc. (Filer) CIK: 0001404281 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36620 | Film No.: 221155676
SIC: 2834 Pharmaceutical Preparations